Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer
Kintara Therapeutics (KTRA) has received Fast Track Designation from the FDA for its REM-001 Therapy aimed at treating cutaneous metastatic breast cancer (CMBC). The therapy has shown an impressive 80% complete response rate in previous trials among patients who had received prior treatment. Kintara, which is currently seeking funding, plans to restart clinical studies to advance this therapy. The Fast Track Designation allows for enhanced FDA access and potential expedited review processes, which may accelerate product approval timelines.
- FDA Fast Track Designation granted to REM-001 Therapy for CMBC, indicating regulatory recognition of its potential.
- 80% complete response rate in clinical trials for CMBC, showcasing the drug's efficacy.
- Strong safety database with approximately 1,100 patients studied, indicating a robust risk profile.
- Kintara has paused the REM-001 CMBC program to conserve cash resources, indicating potential funding challenges.
SAN DIEGO, Nov. 28, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's REM-001 Therapy for the treatment of patients with cutaneous metastatic breast cancer (CMBC).
REM-001 was studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to-date of
"The receipt of Fast Track Designation represents an important regulatory milestone for our REM-001 Therapy program," said Robert E. Hoffman, President and CEO of Kintara. "We believe this designation is a key component of our future clinical and regulatory strategy as we continue to seek funding, in particular grants, to restart REM-001 clinical development as soon as possible."
Dennis Brown, Ph.D., Chief Scientific Officer of Kintara added, "This designation from the FDA emphasizes the important unmet medical need for safe and effective therapeutic options to address CMBC. We have extensive data in hand to support the advancement of this clinical program and look forward to the continued investigation of our drug candidate in the next study as planned."
Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Some of the significant benefits of FTD include:
- Enhanced access to the FDA including opportunities for more frequent meetings and written consultation throughout the remaining development of REM-001.
- Drugs with FTD are eligible to apply for Accelerated Approval and Priority Review at the time of a New Drug Application (NDA) submission, which may result in faster product approval.
- FTD also allows for 'rolling review' where Kintara may submit completed sections of the REM-001 NDA as they become available rather than at the end of development.
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for glioblastoma (GBM) and REM-001 Therapy for CMBC.
VAL-083 is a 'first-in-class', small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the Global Coalition for Adaptive Research registrational Phase 2/3 clinical trial titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study to support the development and commercialization of VAL-083 in GBM.
Kintara also has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of
For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and LinkedIn.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE Study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to regain compliance with The Nasdaq Capital Market's listing standards, the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2022, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.
CONTACTS
Investors
LifeSci Advisors
Mike Moyer, Managing Director
617.308.4306
mmoyer@lifesciadvisors.com
Media inquiries
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
858.717.2310
646.942.5604
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-granted-fast-track-designation-from-fda-for-rem-001-for-cutaneous-metastatic-breast-cancer-301687450.html
SOURCE Kintara Therapeutics
FAQ
What is the significance of the Fast Track Designation for Kintara's REM-001 Therapy?
How effective has REM-001 Therapy been for cutaneous metastatic breast cancer?
What steps is Kintara taking after receiving Fast Track Designation?
How many patients were involved in the safety database for REM-001?
What are the potential benefits of the Fast Track designation for KTRA investors?
